Metoprolol

IV tartrate is labeled for stable acute MI with subsequent oral maintenance. Metoprolol also appears in professional AF rate-control guidance; this is off-label in the selected U.S. labels. Rhythm, hemodynamic status, ventricular function, and the current specialist protocol determine selection.

Take with or immediately after meals. Acute MI initiation and oral transition require professional supervision; do not use the table as an unsupervised start or conversion plan.

Scored Toprol-XL tablets may be divided; do not crush or chew either half. Do not advance HF titration while decompensation persists; symptomatic bradycardia or worsening HF may require dose reduction or temporary interruption by the clinician.

After hemodynamic stabilization in coronary care or an equivalent unit, the selected label specifies three 5 mg IV boluses about 2 minutes apart, with blood pressure, heart rate, and ECG monitoring. Transition to oral therapy according to the oral product label. This MI regimen is distinct from off-label arrhythmia protocols.

Hepatic impairment can markedly increase exposure: begin below the usual indication-specific dose and titrate cautiously. Chronic renal failure alone does not require a label-directed reduction. Consider age, cardiac function, interactions, and the overall clinical state.

Oral labels exclude severe bradycardia, second- or third-degree block, cardiogenic shock, decompensated HF, sick sinus syndrome without a pacemaker, and ingredient hypersensitivity. The selected tartrate tablet label also lists systolic BP <100 mmHg; check the exact product.

The IV label additionally specifies heart rate <45/min, significant first-degree block (PR ≥0.24 seconds), systolic BP <100 mmHg, and decompensated cardiac failure; second/third-degree block is excluded unless a functioning pacemaker is present. It also excludes hypersensitivity to related derivatives or other beta blockers.

Some metoprolol labels present ischemic heart disease and abrupt withdrawal as a boxed warning. The selected Alembic and Toprol-XL labels place the warning in section 5.1. The clinical withdrawal risk remains; verify boxed status on the dispensed product.

Reported effects include tiredness, dizziness, depression, diarrhea, rash, dyspnea, slow pulse, and hypotension. Serious events include heart block, worsening HF, bronchospasm, and severe hemodynamic effects. Frequencies differ by indication and study; the acute MI trial experience is not a general outpatient rate.

Observational data have not shown an association with major congenital malformations, but cannot establish absence of risk. Metoprolol crosses the placenta; untreated maternal cardiovascular disease also carries risk. Observe exposed neonates for bradycardia, hypotension, hypoglycemia, and respiratory depression. Individualize treatment with the obstetric and cardiovascular teams.

Metoprolol enters milk in small amounts in the limited reports; no infant adverse effects were identified in those reports. Monitor the breastfed infant for bradycardia or signs of beta blockade, including listlessness consistent with hypoglycemia.

Toprol-XL has pediatric hypertension dosing from age 6; safety/effectiveness below 6 is not established. Pediatric safety/effectiveness is not established for the selected tartrate tablet or injection. Older adults generally warrant a low starting dose and cautious titration because organ impairment and interacting medicines are common.

Beta blockers may contribute to erectile dysfunction; discuss symptoms rather than interrupting therapy. Hepatic dysfunction increases exposure and warrants lower initiation doses. Chronic renal failure alone does not require dose reduction in the selected oral labels.

Preferential beta₁ antagonism reduces catecholamine-driven cardiac effects and myocardial oxygen demand. Beta₂ blockade increases at higher concentrations. Extended-release delivery supports steadier beta blockade across the daily interval; release behavior does not change the active ingredient.

Metabolism

Predominantly hepatic CYP2D6; poor metabolism or enzyme inhibition raises exposure.

Half-life

Tartrate label: approximately 3–4 hours, prolonged to 7–9 hours in poor CYP2D6 metabolizers. Toprol-XL label reports approximately 3–7 hours.

Elimination

Predominantly urinary inactive metabolites; little oral dose is excreted unchanged.

Distribution

Crosses placenta and blood–brain barrier; present in human milk.

• Check blood pressure, heart rate, dizziness, syncope, and conduction concerns; ECG monitoring is required during IV administration.
• During HF titration, assess dyspnea, edema, weight changes, and stability before increasing the dose.
• Monitor glucose and hypoglycemia symptoms when diabetes, fasting, or vomiting increases risk; a normal pulse does not exclude hypoglycemia.
• Recheck interacting drugs and hepatic function when response or tolerance changes. Monitor for chest pain during taper.

• Take regularly as prescribed; do not change the salt, schedule, or dose without review. Tartrate tablets: take with or immediately after food.
• For a missed oral dose, follow the next scheduled dose without doubling. Never stop abruptly.
• Avoid driving until the effect on alertness is known. Notify the prescriber/dentist before surgery.
• Report new breathing difficulty promptly; seek urgent help for severe fainting, chest pain, or marked breathing distress.

Other manufacturers and strengths differ. Ask a pharmacist to confirm packaging and imprint.

Dosage form / strength

Scored film-coated ER tablet · 25 mg metoprolol tartrate-equivalent labeling

Salt

Metoprolol succinate

Appearance / imprint

White, oval, biconvex · A/β

Example package NDC

70347-025-02 · 100 tablets

Tartrate tablets · Selected manufacturer

25, 50, and 100 mg, functionally scored.

Succinate ER · Toprol-XL

25, 50, 100, and 200 mg tartrate-equivalent strengths.

Tartrate injection · Selected product

1 mg/mL · 5 mg in a 5 mL vial.

Other products

ER capsules and other manufacturers have separate labels and administration instructions.

Selected tartrate tablets: 20–25°C, protected from moisture and heat in a tight, light-resistant container. Toprol-XL: 25°C, permitted excursions 15–30°C. Selected IV vials: 25°C, excursions 15–30°C, protected from light and heat. Keep medicines out of children’s reach and follow the exact package.